Abstract:BackgroundNasopharyngeal cancer (NPC) is common in Southeast Asia, especially in Southern China. Combination of CTLA-4 and PD-1 blockade has consistently demonstrated the increase of the response rates and survival rates of the patients (pts) compared to monotherapy in various tumors.1 Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic NPC,2 suggesting the combination of CTLA-4 and PD-1 blockers have synergistic effect in NPC. Here, this Phase II study present initial safety and efficacy data for AK104, a PD-1/CTLA-4 bispecific antibody, in metastatic NPC pts.MethodsAK104-204 (NCT04220307) is a multicenter, single-arm, open-label study of AK104 in patients (pts) with metastatic NPC who have failed at least two lines of chemotherapy and didn’t receive any anti-PD-1/PD-L1 antibodies previously. All patients received AK104 6 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor proportion score (TPS)=50% was regarded as PD-L1 positive.ResultsAs of 6 June 2021, 23 pts were enrolled. Median age was 43[range:19–64] years old, 87.0% was male, 73.9% ECOG performance status was 1. Of 20 efficacy-evaluable pts, the confirmed ORR was 30% (6/20); the disease control rate (DCR) was 70% (14/20). Among them, the ORR was 57.1% (4/7) in pts with PD-L1 positive and the 18.2% (2/11) in pts with PD-L1 negative. Grade 3 treatment-related adverse events (TRAEs) occurred in 21.7% (5/23) of pts. No Grade 4 or 5 TRAEs occurred. Most frequent TRAEs (incidence = 20%) were anaemia (30.4%), white blood cell count decreased (26.1%), hypothyroidism (26.1%), neutrophil count decreased (21.7%), and rash (21.7%).ConclusionsAK104 demonstrated encouraging anti-tumor activity and favorable safety profile in pts with NPC who had disease progression after =2 prior lines of therapy. NPC pts with PD-L1–positive tumors receiving AK104 showed more benefits than those with PD-L1-negative tumors. AK104 for the treatment of NPC should be further evaluated.AcknowledgementsAkeso Biopharma, Inc would like to thank the patients, investigators and site staff for their participation in this study.Trial RegistrationClinical registration number: NCT04220307ReferencesRotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental & Clinical Cancer Research 2019, 38(1): 1–12.Annals of Oncology 2020;3(suppl_6): S1347-S1354. 10.1016/annonc/annonc360.Ethics ApprovalThis study received ethics approval from Ethics Committee of Sun Yat-Sen University Cancer Center on 04 Dec 2019 (Approval number: A2019-085-01). In accordance with ICH Good Clinical Practice Guidelines and the Declaration of Helsinki, study participants gave informed consent voluntarily before participating in this study.ConsentWritten informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

Clinical Response and Biomarker Analysis of POLARIS-02 a Phase II Study of Toripalimab, a Humanized IgG4 Mab Against Programmed Death-1 (PD-1) in Patients with Metastatic Nasopharyngeal Carcinoma.

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (Js001) In Patients With Refractory/Metastatic Nasopharyngeal Carcinoma: Interim Results Of An Open-Label Phase Ii Clinical Study.

Anti-LAG-3 Antibody LBL-007 in Combination with Anti-Pd-1 Antibody Tislelizumab with or Without Chemotherapy in Patients with Advanced Nasopharyngeal Cancer and Other Malignant Tumors: A Phase Ib/II Dose Escalation/expansion Study

Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.

Tislelizumab, an Investigational Anti-Pd-1 Antibody, Combined with Chemotherapy As First-Line Treatment for Lung Cancer in Chinese Patients.

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Efficacy and Safety of QL1706, a Novel Dual Immune Checkpoint Blockade Containing a Mixture of Anti-Pd1 IgG4 and Anti-Ctla4 IgG1 Antibodies, for Advanced Nasopharyngeal Carcinoma (NPC): Pooled Cohort Data from Phase 1a/1b Trials.

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma.

A real-world evaluation of tislelizumab in patients with head and neck cancer

Neoadjuvant Docetaxel-Cisplatin Followed by Concurrent Chemoradiotherapy and Adjuvant Tislelizumab for Locally Advanced Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase II Trial.

436 A Phase II Study of AK104, a Bispecific Antibody Targeting PD-1 and CTLA-4, in Patients with Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Progressed after Two or More Lines of Chemotherapy

Efficacy and Safety of Camrelizumab and Apatinib Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy for Stage T Any N3M0 Nasopharyngeal Carcinoma: A Phase II QUINTUPLED Trial.